An observational study in Atrial Fibrillation (AF), sponsored by Ting-Yung Chang. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by Ting-Yung Chang · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Atrial Fibrillation with a site in Taiwan — 17 open to participants now, 25 under way, 3 of them phase 3. Atrial Fibrillation · Taiwan.
Among the 95 studies in Atrial Fibrillation with a site in Taiwan, this one is the 20th largest by planned enrollment of the 25 observational ones that give a count, is one of 9 that started in 2025, is one of 27 observational ones, reaches primary completion later than 12 of the 24 other live ones, and was the 82nd registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →17 of the 95 studies in Atrial Fibrillation with a site in Taiwan are open now. Recruiting first, the newest first:
National Cheng-Kung University Hospital · Sites in Taiwan
Ages 18–80
Boston Scientific Corporation · Sites in Taiwan, Croatia, Czechia and 1 more country
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 20+
National Defense Medical Center, Taiwan · Sites in Taiwan
Ages 40 days–85 days
Tze-Fan Chao · Sites in Taiwan
Ages 20+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 24 · Phase 4 4
First in 2003; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 448 across the 67 interventional studies, 343 across the 25 observational. Of the 57 that completed or were terminated, 29 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 95 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Ting-Yung Chang as lead sponsor.
Ting-Yung Chang has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
5 of the studies in Atrial Fibrillation with a site in Taiwan that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06111443Phase 3Chang Gung Memorial HospitalEffect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation | 2026-11-30 |
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT06632925Taipei Veterans General Hospital, TaiwanUtility of Analyzing Atrial Signal Electrograms in Patients with Atrial Fibrillation Using Next-Generation Ensite X Software: a Prospective Study | 2027-01-01 |
| NCT06735534Boston Scientific CorporationRepeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | 2027-04 |
| NCT06960252Ting-Yung ChangCycle-Length Mapping in Patients With Non-paroxysmal Atrial Fibrillation | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 95 studies in Atrial Fibrillation with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The critical atrial substrates in maintaining persistent atrial fibrillation might be identified by Cycle-Length Mapping (CLM) module. Based on the results of multicenter study in Cycle-Length Mapping between Taipei Veterans General Hospital (Professor Shih-Ann Chen) and IRCCS San Donato Policlinic (Professor Carlo Pappone), targeted CLM driver-ablation provided significant benefits in terms of arrhythmia freedom in the treatment of persistent AF. These findings support a patient-tailored, mapping-based strategy for individuals affected by non-paroxysmal AF. The new ultra-high density mapping catheter, OPTRELL, will be available soon in Taiwan. Therefore, we proposed that the degree of atrial interstitial fibrosis detected by using both unipolar and bipolar voltage map in sinus rhythm and CLM in AF with OPTRELL™ Mapping Catheter would be further better characterization of the atrial substrate and could be potentially critical targeted in eliminating the sources of AF.
As additional substrate mapping provided benefits compared to PVI alone in patients with persistent AF, we hypothesize that combination of electrophysiological and substrate-guided ablation strategy using CLM module with OPTRELL™ Mapping Catheter could be used to guide radiofrequency ablation in the patient with non-paroxysmal atrial fibrillation.
non-paroxysmal AF
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
non-paroxysmal AF admitted for catheter ablation
Device: OPTRELL™ Mapping Catheter
PVI plus substrate modification of LA chamber coexisting with low unipolar voltage (\< 3.0 mv) or bipolar voltage (\< 0.5 mv) in SR and stable (STD \< 30), fast AF CL detected by CLM module and OPTRELL™ Mapping Catheter.
Efficacy endpoint
The endpoints are recurrence of all atrial arrhythmia, including AF, atrial flutter, and atrial tachycardia, and defined as an episode lasting \> 30 seconds, 3 months after the ablation, during follow-up with ambulatory ECG monitoring every 3 months.
Time frame: 12 months
Started Aug 2025 (actual). Primary completion is estimated for Aug 2027, 24 months after the start.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 24 months is below that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.